ALPK3心肌病:综合性综述与系统变异修复,机制和翻译
Chien-Wei Chang1,2, Li Wang1, Zeyu Chen1
1Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego (C.-W.C., L.W., Z.C., J.B., J.C.).
Circulation. Genomic and precision medicine
|November 12, 2025
概括
在ALPK3的致病变体导致严重的心肌病. 双性功能丧失导致早期发病,而异性变体则导致过度缩性心肌病变. 基因替代和药物疗法对ALPK3心肌病有前途.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 遗传医学是一种遗传医学.
背景情况:
- ALPK3 (α-蛋白激酶3) 的致病变体与心肌病症有关.
- ALPK3 作为一种 Sarcomeric M-band 支架蛋白,对 Sarcomere 稳定性和蛋白质稳定性至关重要.
- 疾病的严重程度与ALPK3变异的致死性相关.
研究的目的:
- 综合审查和整理ALPK3变体和心肌病的临床和实验数据.
- 阐明ALPK3相关心肌病的分子机制.
- 评估ALPK3心肌病的治疗策略.
主要方法:
- 在2025年6月9日之前,对同行评审报告和患者级数据进行系统的策划.
- 临床前模型的分析,包括人类诱导的多能干细胞衍生的心肌细胞和小鼠模型.
- 对治疗干预措施的审查,包括药理学药物和基因替代疗法.
主要成果:
- 双性功能丧失ALPK3变体导致严重的,往往致命的,早期发作的心肌病与心脏外表现.
- 异体蛋白切断ALPK3变体占成年人多性心肌病病例的1-4%,通常具有特定的多性模式和纤维化.
- 失去ALPK3支架功能会导致MYOM移位,厚丝聚合和收缩功能障碍.
- 用mavacamten (肌肉酶抑制剂) 和miniALPK3基因替代在小鼠模型中进行的治疗概念验证.
结论:
- ALPK3心肌病是一种显著的遗传性疾病,其临床表现基于结合性而异.
- 分子机制涉及由于ALPK3脚手架功能的丧失而破坏了sarcomeric蛋白质稳定.
- ALPK3心肌病变是精准医学的一个可行的目标,基因替代和向疗法提供了潜在的疾病修饰治疗方法.
更多相关视频
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
4.2K
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
1.7K
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
01:25Cardiomyopathy I: Introduction and Classification
488
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
488
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
438
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
438
01:29Cardiomyopathy V: Interprofessional Care
323
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
323
01:30Cardiomyopathy II: Dilated Cardiomyopathy
451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451